Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

SELLAS Life Sciences (SLS) Net Income towards Common Stockholders (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Net Income towards Common Stockholders for 9 consecutive years, with -$6.7 million as the latest value for Q4 2024.

  • Quarterly Net Income towards Common Stockholders rose 17.2% to -$6.7 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$30.9 million through Dec 2024, up 17.71% year-over-year, with the annual reading at -$26.9 million for FY2025, 13.01% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2024 was -$6.7 million at SELLAS Life Sciences, up from -$7.1 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$2.4 million in Q1 2021, with the low at -$16.7 million in Q1 2022.
  • Average Net Income towards Common Stockholders over 5 years is -$7.4 million, with a median of -$7.1 million recorded in 2022.
  • The sharpest move saw Net Income towards Common Stockholders soared 61.0% in 2020, then plummeted 596.42% in 2022.
  • Over 5 years, Net Income towards Common Stockholders stood at -$3.7 million in 2020, then crashed by 77.56% to -$6.6 million in 2021, then crashed by 43.16% to -$9.4 million in 2022, then increased by 13.87% to -$8.1 million in 2023, then rose by 17.2% to -$6.7 million in 2024.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$6.7 million, -$7.1 million, and -$7.5 million for Q4 2024, Q3 2024, and Q2 2024 respectively.